<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701595</url>
  </required_header>
  <id_info>
    <org_study_id>RODEO 2</org_study_id>
    <nct_id>NCT02701595</nct_id>
  </id_info>
  <brief_title>Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus</brief_title>
  <official_title>Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites Ã  Streptocoques Multi-sensibles)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infective endocarditis (IE) is a serious infection with a significant burden for patients and
      hospitals (in France, median length of hospital stay = 43 days), partly due to the long
      duration of intravenous (IV) antibacterial treatment recommended by international guidelines,
      between 4 and 6 weeks in most situations.

      A recent survey of practices regarding the management of IE in France showed that a switch
      from IV to oral antibiotics is feasible, when patients with left-sided
      Streptococcus-Enterococcus IE are stable after an initial course of IV antibiotic treatment,
      with or without valvular surgery.

      These practices have not been associated with unfavourable outcome, while significantly
      reducing the duration and cost of hospitalization, the risk of nosocomial infection, and
      patients' discomfort.

      There has been no randomized controlled trial (RCT) in the field of IE over the last 20
      years; current guidelines are mostly based on expert advice, in vitro studies, animal
      experiments, or clinical studies performed before the 90's.

      The RODEO 2 project is an unprecedented opportunity to bring back evidence-based medicine in
      the field of IE.

      Most experts acknowledge that the pharmacological PK/PD characteristics of antibiotics such
      as amoxicillin allow a high level of efficacy in the treatment of IE when orally
      administrated after an IV period of induction.

      It's needed to conduct RCTs that clearly demonstrate the clinical non-inferiority of this
      strategy for streptococci, and enterococci IE with a benefit regarding costs.

      The RODEO 2 project corresponds to one pragmatic trial assessing the impact of a switch
      strategy, making it a comparative effectiveness trial that should be able to feed the next
      revision of IE international guidelines and to change practices in IE management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RODEO 2 study is designed to determine the safety and efficacy of partial oral treatment
      of IE compared with traditional full-length parenteral treatment. Our primary objective is to
      demonstrate that in patients with left-sided multi-susceptible Streptococcus-Enterococcus IE
      who have received at least 10 days of IV antibiotic treatment with or without valvular
      surgery, a switch to an oral combination of amoxicillin between Day 10 and Day 28 after
      initiation of the IV antibiotic treatment, is not inferior to the continuation of the
      conventional IV antibiotic treatment regarding to treatment failure within 3 months after the
      end of antibiotic treatment.

      Nationwide, noninferiority, multicenter, randomized, controlled, open-label trials.

      Randomisation will only be offered to patients who have received at least 10 days of IV
      conventional antibiotic treatment of IE, and fulfil the inclusion criteria.

      Randomisation will take place between Day 10 and Day 28 after initiation of parenteral
      antibiotic therapy or valvular surgery, thus ensuring to have at least 14 days of oral
      therapy in the experimental group.

      Patients will be eligible whether they have undergone valvular surgery or not. This will
      imply that surgery procedure prior to randomisation will be heterogeneous, but randomisation
      will be stratified on the requirement of valvular surgery as part of the treatment of the
      current episode of IE or not.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>Failure is a composite outcome defined by death from all causes and/or symptomatic embolic events and/or unplanned valvular surgery and/or a microbiological relapse (with the primary pathogen).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from all-cause</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>death from all-causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of symptomatic embolic events</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>secondary osteo-articular, splenic or brain localization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unplanned valvular surgery</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>unplanned valvular surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse of positive blood cultures</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>relapse of positive blood cultures with the primary pathogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiological relapse with a different pathogen from the primary pathogen</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment]</time_frame>
    <description>Relapse of positive blood cultures with a different pathogen within 3 months after the end of antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>An apparition, an increase or decrease of the following items: vegetation, abscess, perforation, fistula, dehiscence of a prosthetic valve, will be searched at each ultrasound examination at : the end of antibiotic treatment, at 3 months and 6 months after the end of antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter related adverse events</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>Catheter-related AE: infectious (e.g. catheter-related bacteraemia) or non-infectious catheter-related complications (e.g. extravasation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other healthcare-acquired infections</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>other healthcare-acquired infections, including urinary tract infections, pneumonia, surgical site infection, Clostridium difficile infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an antibiotic modification</measure>
    <time_frame>up to the end of antibiotic treatment</time_frame>
    <description>All change regarding antibiotic treatment administered will be recorded (drug, dose or duration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>An assessment of patient's quality of life will be done at the end of antibiotic treatment, at 3 months and 6 months after the end of antibiotic treatment, using the EuroQol Five Dimensions (EQ5D3L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>numer of participants with a switch back from oral to IV antibiotic treatment</measure>
    <time_frame>up to the end of antibiotic treatment</time_frame>
    <description>For experimental group only . An assessment of the need for a return to parenteral antibiotic in the experimental group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with oral antibiotic treatment</measure>
    <time_frame>up to 4 weeks after randomisation</time_frame>
    <description>For experimental group only. The assessment of compliance with oral antibiotic treatment will be carried out at each visit during the treatment period though a &quot;patient book&quot; which will permit to note take/omissions of treatment; and though the return of the treatments to the pharmacy of the investigational site.
Calculation of the duration and cumulative dose of antibiotic treatment actually received will be performed, and compared to the regimen prescribed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per patient</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>Analysis using data from three centers (Tours, Rennes, Nancy) to compare both strategy (oral switch vs. pan-IV) for the cost per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Budget impact analysis (BIA)</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>With data from three centers (Tours, Nancy, Rennes). With data from three centers (Tours, Nancy, Rennes). Allow to estimate the financial consequences of the adoption and diffusion of a new health intervention (the oral strategy). BIA must be calculated on a yearly basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility score and incremental cost-utility ratio (ICUR)</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>With data from all centers. An assessment of the health related quality of life of the patient will be carried out using a simple generic questionnaire, the EuroQol Five Dimensions (EQ5D3L), recommended by the Washington Panel on Cost Effectiveness (utility) in Health and Medicine, with a cardinal scale and validated French version (http:// www.euroqol.org)Quality of life will be assessed 4 times: at baseline, at the end of antibiotic treatment, at 3 months after end of antibiotic treatment and at the final visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>With data from all centers. Length of hospital stay will be calculated as duration between day of start of hospitalization and day of discharge (distinguishing rehabilitation care unit). In case a patient dies during hospitalization, death will be considered as a competing event to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual concentration of antibiotics</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic analysis for the experimental group only: residual concentrations of levofloxacin and rifampicin, or amoxicillin, after 7 days of oral treatment (i.e. at visit 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological collection for further analysis on endocarditis</measure>
    <time_frame>up to 6 months after the end of antibiotic treatment</time_frame>
    <description>A biological collection will be constituted in order to perform further biological and genetic analysis of endocarditis (i.e. inflammatory markers of efficacy and genetic markers that predispose to endocarditis).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Infective Endocarditis</condition>
  <arm_group>
    <arm_group_label>Oral switch treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral switch to amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional IV treatment according to european guidelines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>amoxicillin 1500 mg x3/day (for patients â¤70kg) or 2000 mg x3/day (for patients &gt;70kg)</description>
    <arm_group_label>Oral switch treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin</intervention_name>
    <description>Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin</description>
    <arm_group_label>Conventional IV treatment according to european guidelines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Left-sided IE (Defined according to Duke criteria) on native or prosthetic valve

          -  due to one isolate of Streptococcus/Enterococcus sp. susceptible to amoxicillin (MCI â¤
             0.125 mg/l)

          -  in an adult â¥18 year old

          -  appropriate parenteral antibiotics treatment received for at least 10 days

          -  in case of valvular surgery, appropriate parenteral antibiotics treatment received for
             at least 10 days after valvular surgery

          -  planned duration of antibiotics will extend for at least 14 days at the time of
             randomisation i.e. a potential switch to oral treatment between Day 10 and Day 28 thus
             ensuring to have at least 14 days of oral therapy remaining in the experimental group

          -  apyrexia (temperature &lt; 38Â°C) at each time point during the last 48 hours (at least
             two measures/day) at the time of randomisation

          -  blood cultures have been sterile for at least 5 days at the time of randomisation

          -  informed, written consent obtained from patient

          -  subject covered by or having the rights to French social security

        Exclusion Criteria:

          -  body mass index &lt;15 kg/mÂ² or &gt; 40 kg/mÂ²

          -  glomerular filtration rate &lt; 60 ml/min/1,73mÂ²

          -  patient unable or unwilling to take oral treatment (digestive intolerance, significant
             malabsorption) at the time of randomisation

          -  expected difficulties regarding compliance with oral antibiotic treatment or follow-up
             (e.g. severe cognitive impairment, severe psychiatric disease...)

          -  patient without entourage to support and watch him at discharge

          -  valvular surgery planned within the next 6 months

          -  for patients with cardiac devices (pace-maker, implantable cardiac defibrillator) and
             suspected device-related IE (vegetation on the leads) if removal of the device was not
             performed

          -  breast feeding or pregnant women, or women on childbearing age without effective
             contraception

          -  expected duration of follow-up &lt; 7 months at the time of randomisation (e.g. expected
             life expectancy &lt; 7 months, patient living abroad...)

          -  past medical history of IE in the last 3 months

          -  other infection requiring parenteral antibiotic therapy

          -  taking of an estrogen-progesterone treatment interacting with rifampicin

          -  patient with contra-indication to oral antibiotics administered in the experimental
             arm (i.e. amoxicillin) - including anticipated non-manageable drug interactions, and
             allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis BERNARD, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louis BERNARD, MD, PHD</last_name>
    <email>L.BERNARD@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AurÃ©lie DARMAILLACQ</last_name>
    <phone>02.47.47.46.38</phone>
    <email>a.darmaillacq@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service des maladies infectieuses, Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence MAULIN, Dr</last_name>
      <phone>04 42 33 90 13</phone>
      <email>lmaulin@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence MAULIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de court sÃ©jour gÃ©riatrique - EMG, Centre hospitalier d'AlÃ¨s</name>
      <address>
        <city>AlÃ¨s</city>
        <zip>30103</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibaut FRAISSE, Dr</last_name>
      <phone>04 66 78 31 56</phone>
      <email>dr.fraisse@ch-ales.fr</email>
    </contact>
    <investigator>
      <last_name>Thibaut FRAISSE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pathologies infectieuses et tropicales, HÃ´pital Nord, CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Phillipe LANOIX, Dr</last_name>
      <phone>03 22 66 88 13</phone>
      <email>lanoix.jean-philippe@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Phillipe LANOIX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et Tropicales, HÃ´pital Jean Minjoz, CHU de BesanÃ§on</name>
      <address>
        <city>BesanÃ§on</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CHIROUZE, Pr</last_name>
      <phone>03 22 66 88 13</phone>
      <email>cchirouze@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine CHIROUZE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales, HÃ´pital Avicenne, APHP</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FrÃ©dÃ©ric MECHAI, Dr</last_name>
      <phone>01 48 95 78 13</phone>
      <email>frederic.mechai@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>FrÃ©dÃ©ric MECHAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation mÃ©dicale, HÃ´pital St AndrÃ©, CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice CAMOU, Dr</last_name>
      <phone>05 56 79 58 30</phone>
      <email>fabrice.camou@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice CAMOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de mÃ©decine interne, HÃ´pital Ambroise ParÃ©, APHP</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth ROUVEIX NORDON, Pr</last_name>
      <phone>01 49 09 56 45</phone>
      <email>elisabeth.rouveix@apr.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth ROUVEIX NORDON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses, HÃ´pital de la Cavale Blanche, CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SÃ©verine ANSART, Pr</last_name>
      <phone>02 98 34 71 91</phone>
      <email>severine.ansart@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, HÃ´pitall Louis Pradel, HÃ´pitaux Est, Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FranÃ§ois DELAHAYE, Pr</last_name>
      <phone>04 72 35 76 28</phone>
      <email>francois.delahaye@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>FranÃ§ois DELAHAYE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Maladies Infectieuses et tropicales, HÃ´pital CÃ´te de Nacre, CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud VERDON, Pr</last_name>
      <phone>02 31 06 47 14</phone>
      <email>verdon-r@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Renaud VERDON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales mÃ©decine interne, CH MÃ©tropole Savoie</name>
      <address>
        <city>ChambÃ©ry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel FORESTIER, Dr</last_name>
      <phone>04 79 96 58 47</phone>
      <email>emmanuel.forestier@ch-metropole-savoie.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel FORESTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses et tropicales, HÃ´pital G. Montpied, CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali VIDAL, Dr</last_name>
      <phone>04 73 75 44 05</phone>
      <email>mvidal@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Magali VIDAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DÃ©partement d'infectiologie, Complexe Bocage, HÃ´pital d'enfants, CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel PIROTH, Pr</last_name>
      <phone>03 80 29 36 31</phone>
      <email>lionel.piroth@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel PIROTH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine interne polyvalente et neurologique CH de Douai</name>
      <address>
        <city>Douai</city>
        <zip>59507</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier LEMAIRE, Dr</last_name>
      <phone>03 27 94 74 50</phone>
      <email>xljhe@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier LEMAIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de mÃ©decine aigue spÃ©cifique, HÃ´pital Raymond PoincarÃ©, APHP</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AurÃ©lien DINH, Dr</last_name>
      <phone>01 47 10 44 32</phone>
      <email>aurelien.dinh@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>AurÃ©lien DINH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de mÃ©decine post-urgence, infectiologie, Site de la Roche sur Yon, CHD VendÃ©e</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas GUIMARD, Dr</last_name>
      <phone>02 51 44 63 85</phone>
      <email>thomas.guimard@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GUIMARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine infectieuse, HÃ´pital Nord Michallon, CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier EPAULARD, Pr</last_name>
      <phone>04 76 76 52 91</phone>
      <email>OEpaulard@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier EPAULARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales, et pathologie VIH, HÃ´pital A Mignot, CH de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alix GREDER-BELAN</last_name>
      <phone>01 39 63 80 10</phone>
      <email>agreder@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Alix GREDER-BELAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hikombo HITOTO</last_name>
      <phone>02 43 43 26 14</phone>
      <email>hhitoto@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Hikombo HITOTO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UnitÃ© mÃ©dicale d'infectiologie, HÃ´pital Huriez, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine FAURE, Pr</last_name>
      <phone>03 20 44 57 43</phone>
      <email>karine.faure@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Karine FAURE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies Infectieuses et tropicales, HÃ´pital Dupuytren, CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HÃ©lÃ¨ne DUROX, Dr</last_name>
      <phone>05 55 05 66 44</phone>
      <email>helene.durox@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>HÃ©lÃ¨ne DUROX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la sauvegarde</name>
      <address>
        <city>Lyon</city>
        <zip>69337</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck SIBELLAS, Dr</last_name>
      <phone>04 72 20 28 00</phone>
      <email>fsibellas@capio.fr</email>
    </contact>
    <investigator>
      <last_name>Franck SIBELLAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses, HÃ´pital Gui de CHauliac, CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Le Moing, Pr</last_name>
      <phone>04 67 33 77 14</phone>
      <email>v-le_moing@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Le Moing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales, HÃ´pital HÃ´tel Dieu, CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David BOUTOILLE, Pr</last_name>
      <phone>02 40 08 33 55</phone>
      <email>David.Boutoille@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>David BOUTOILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Infectiologie, HÃ´pital de l'Archet, CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa DEMONCHY, Dr</last_name>
      <phone>04 92 03 54 61</phone>
      <email>demonchy.e@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Elisa DEMONCHY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses, CH de Niort</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon SUNDER, Dr</last_name>
      <phone>05 49 78 30 75</phone>
      <email>simon.sunder@ch-niort.fr</email>
    </contact>
    <investigator>
      <last_name>Simon SUNDER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales, HÃ´pital CarÃ©meau, CHU de NÃ®mes</name>
      <address>
        <city>NÃ®mes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine LECHICHE, Dr</last_name>
      <phone>04 66 68 41 49</phone>
      <email>catherine.lechiche@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine LECHICHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales, HÃ´pital de la Source, CHR OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent HOCQUELOUX, Dr</last_name>
      <phone>02 38 22 95 88</phone>
      <email>laurent.hocqueloux@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent HOCQUELOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Microbiologie, HÃ´pital EuropÃ©en Georges Pompidou, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc MAINARDI, Pr</last_name>
      <phone>01 56 09 22 54</phone>
      <email>jean-luc.mainardi@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc MAINARDI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales, HÃ´pital Necker, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline CHARLIER, Dr</last_name>
      <phone>01 44 49 52 62</phone>
      <email>caroline.charlier@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline CHARLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de maladies infectieuses, parasitaires et tropicales, HÃ´pital Bichat, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Marie DUVAL, Pr</last_name>
      <phone>01 40 25 88 92</phone>
      <email>xavier.duval@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Marie DUVAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, CH de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>AurÃ©lia EDEN, Dr</last_name>
      <phone>05 49 78 30 75</phone>
      <email>aurelia.eden@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>AurÃ©lia EDEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine interne, maladies infectieuses et tropicales, CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume BERAUD, Dr</last_name>
      <phone>05 49 44 40 04</phone>
      <email>beraudguillaume@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Guillaume BERAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectiologie, mÃ©decine interne et mÃ©decine des voyages, CH d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre BRU, Dr</last_name>
      <phone>04 50 63 66 02</phone>
      <email>jpbru@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre BRU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine interne, maladies infectieuses, immunologie clinique, HÃ´pital R. DebrÃ©, CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FirouzÃ© BANI SADR, Pr</last_name>
      <phone>03 26 78 71 89</phone>
      <email>fbanisadr@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>FirouzÃ© BANI SADR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses et rÃ©animation mÃ©dicale, HÃ´pital Pontchaillou, CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre TATTEVIN, Pr</last_name>
      <phone>02 99 28 95 64</phone>
      <email>pierre.tattevin@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre TATTEVIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, HÃ´pital Charles Nicolle, CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire CHAPUZET, Dr</last_name>
      <phone>02 32 88 87 39</phone>
      <email>claire.chapuzet@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Claire CHAPUZET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des maladies respiratoires et infectieuses, CH de St Malo</name>
      <address>
        <city>Saint Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu DUPONT, Dr</last_name>
      <phone>02 99 21 21 70</phone>
      <email>m.dupont@ch-stmalo.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu DUPONT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladie infectieuses et tropicales, HÃ´pital d'instruction des armÃ©es BÃ©gin</name>
      <address>
        <city>Saint-Mande</city>
        <zip>94163</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe RAPP, Pr</last_name>
      <phone>01 43 98 48 37</phone>
      <email>Rappchristophe5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Christophe RAPP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, HÃ´pital de Purpan, CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lydie PORTE, Dr</last_name>
      <phone>05 61 77 91 17</phone>
      <email>porte.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Lydie PORTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric SENNEVILLE, Pr</last_name>
      <phone>03 20 69 48 48</phone>
      <email>esenneville@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Eric SENNEVILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine interne et maladies infectieuses, HÃ´pital Bretonneau, CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis BERNARD, Pr</last_name>
      <phone>02 18 37 06 44</phone>
      <email>L.BERNARD@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Louis BERNARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales, HÃ´pitaux de Brabois, CHU de Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FranÃ§ois GOEHRINGER, Dr</last_name>
      <phone>03 83 15 40 98</phone>
      <email>f.goehringer@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>FranÃ§ois GOEHRINGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultation de MÃ©decine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges</name>
      <address>
        <city>Villeneuve St Georges</city>
        <zip>94190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier PATEY, Dr</last_name>
      <phone>01 43 86 20 81</phone>
      <email>Olivier.patey@chiv.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier PATEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69626</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand ISSARTEL, Dr</last_name>
      <phone>08 26 10 12 01</phone>
      <email>bertrand.issartel@vaccination-lyon.com</email>
    </contact>
    <investigator>
      <last_name>Bertrand ISSARTEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
    <mesh_term>Netilmicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

